share_log

メディシノバなどが引き続きランクイン、ALS(筋萎縮性側索硬化症)対象の治験開始へ

美第奇新星生物技術等繼續名列榜首,已開始進行ALS(肌萎縮側索硬化症)的臨床試驗。

Fisco日本 ·  09/23 21:36

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論